Split History
AGEN split history picture
Agenus (AGEN) has 1 split in our AGEN split history database. The split for AGEN took place on April 26, 2023. This was a 1019 for 1000 split, meaning for each 1000 shares of AGEN owned pre-split, the shareholder now owned 1019 shares. For example, a 1000 share position pre-split, became a 1019 share position following the split.

When a company such as Agenus splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the AGEN split history from start to finish, an original position size of 1000 shares would have turned into 1019 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Agenus shares, starting with a $10,000 purchase of AGEN, presented on a split-history-adjusted basis factoring in the complete AGEN split history. AGEN split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 03/31/2014
End date: 03/27/2024
Start price/share: $3.11
End price/share: $0.56
Dividends collected/share: $0.00
Total return: -81.99%
Average Annual Total Return: -15.76%
Starting investment: $10,000.00
Ending investment: $1,800.48
Years: 10.00
Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules. According to our AGEN split history records, Agenus has had 1 split.
Date Ratio
04/26/20231019 for 1000
AGEN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

AGLE Split History
AGN Split History
AGRX Split History
AHPI Split History
AIMT Split History
AIQ Split History
AIRM Split History
AKER Split History
ALBO Split History
ALC Split History

Also explore: AGEN shares outstanding history

Email EnvelopeFree AGEN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

NRx Pharmaceuticals, Inc. (NRXP)
Tritium DCFC Limited (DCFC)
Pluri Inc. (PLUR)
Rent the Runway, Inc. (RENT)
Castor Maritime Inc. (CTRM)
ETAO International Co., Ltd. (ETAO)
Aterian, Inc. (ATER)
Chipotle Mexican Grill, Inc. (CMG)
Moleculin Biotech, Inc. (MBRX)
Longeveron Inc. (LGVN)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

AGEN Insider Buying

AGEN Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.